Review
Published on 12 Jun 2024
MUC21: a new target for tumor treatment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1410761
- 700 views
Type at least 3 characters
1,695 articles
Articles
Case Report
Published on 12 Jun 2024
Case report: Innovative treatment for one metastatic thyroid-like follicular carcinoma of the kidney with ATM and POLE mutations
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1352865
- 412 views
Original Research
Published on 12 Jun 2024
Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1394653
- 408 views
Editorial
Published on 11 Jun 2024
Editorial: Editor's challenge: Dr. Qingxin Mu - how can nanomedicine approaches advance multi-targeting strategy in combination cancer therapy?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1437497
- 266 views
Case Report
Published on 10 Jun 2024
Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1406616
- 336 views
Original Research
Accepted on 05 Jun 2024
Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1390452
Brief Research Report
Published on 30 May 2024
Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1384277
- 951 views
Review
Published on 28 May 2024
Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1405491
- 895 views
Mini Review
Published on 28 May 2024
Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1390006
- 743 views
Perspective
Published on 24 May 2024
Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1391464
- 962 views
Editorial
Published on 23 May 2024
Editorial: Novel therapeutic targets of gastric carcinogenesis: from basic research to drug development and clinical application
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1431520
- 277 views
Mini Review
Published on 22 May 2024
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1394702
- 1,248 views
Original Research
Published on 17 May 2024
The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1402651
- 540 views
Systematic Review
Published on 16 May 2024
Evolution and impact of molecular glue research: a bibliometric analysis from 2000 to 2023
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1401257
- 850 views
Retraction
Published on 14 May 2024
Retraction: Exosomes derived from microRNA-148b-3p-overexpressing human umbilical cord mesenchymal stem cells restrain breast cancer progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1422567
- 422 views
Original Research
Published on 14 May 2024
Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1399574
- 697 views